Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813969 · ClinicalTrials.gov registry record · Phase 1
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
A Phase 1 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00813969 is a Phase 1 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 24 participants.
The verdict
NCT00813969, a Phase 1 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, involving approximately 24 ambulatory participants with relapsing forms of MS (approximately equal numbers with relapsing-remitting and secondary progressive/ progressive relapsing MS) and evidence of involvement of the anterior afferent visual system.
Interventions
- BIOLOGICAL Autologous mesenchymal stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00813969
The ClinicalTrials.gov registry entry for NCT00813969 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous mesenchymal stem cell transplantation is the first listed.
NCT00813969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00813969 about?
NCT00813969 is a clinical study titled "Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS". The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, involving approximately 24 ambulatory participants with relapsing forms of MS (approximately equal numbers with relapsing-remitting and secondary progressive/ progressive relapsing ...
What is the current status of trial NCT00813969?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00813969?
The interventions under investigation include: Autologous mesenchymal stem cell transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT00813969?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.